The landscape of cancer treatment is undergoing a fundamental shift, moving beyond traditional methods of protein inhibition toward a more profound and comprehensive therapeutic strategy: targeted protein degradation (TPD). This innovative approachRead More…
In the ever-evolving landscape of biomedical research, targeted protein degradation (TPD) has emerged as a transformative approach with the potential to redefine disease treatment. By selectively eliminating pathogenic proteins, this technology addressesRead More…
Hello, fellow science enthusiasts! Today, we’re diving into the fascinating world of cancer therapeutics, where the quest for precision and efficacy is ever-evolving. Groundbreaking research has introduced a novel approach to tackleRead More…
Traditional chemotherapy has been a vital tool in cancer treatment for decades, targeting rapidly dividing cancer cells. However, its lack of specificity leads to significant side effects, and drug resistance remains aRead More…
The field of drug discovery is witnessing a revolutionary shift with the advent of Proteolysis Targeting Chimeras (Protein Degraders). This innovative therapeutic strategy is redefining how we approach the degradation of proteins,Read More…
Proteolysis targeting chimera (Protein Degrader) technology represents a breakthrough development in the field of drug discovery, utilizing the ubiquitin proteasome system to specifically degrade disease-related proteins. Protein Degraders are characterized by theirRead More…
Targeted protein degradation (TPD) has emerged over the past decade as a major novel drug modality for the removal of intracellular proteins with bispecific small molecules that recruit proteins of interest (POIs)Read More…
Targeted protein degradation (TPD) primarily degrades target proteins through the ubiquitin-proteasome and lysosome, and according to the specific mechanism of action, it can be further subdivided into nearly 10 different technical routes,Read More…
Introduction Various types of delivery systems, including organic/inorganic nanoparticles, small molecule targeting moieties, and antibodies, have been explored as carriers for Protein Degraders. These systems play a crucial role in addressing theRead More…
Preclinical evidence of Protein Degrader The breakthrough in Protein Degrader’s design paves the way for its early clinical trials. According to statistics, as of January 8, 2023, 18 kinds of Protein DegraderRead More…